Skip to main content

Table 2 Cell viabilities in the presence of DOPAC–Fe3O4@TiO2 nanoconjugates following irradiation

From: Development of Fe3O4 core–TiO2 shell nanocomposites and nanoconjugates as a foundation for neuroblastoma radiosensitization

DOPAC–Fe3O4@TiO2

0 nM

100 nM

250 nM

SK-N-AS

0 Gy

100 ± 5.06

100 ± 4.50

100 ± 10.11

2 Gy

91.84 ± 5.50

57.60 ± 7.28***

53.50 ± 6.60***

5 Gy

59.38 ± 4.79

26.40 ± 5.56***

17.94 ± 4.54***

10 Gy

38.11 ± 2.35

14.53 ± 3.50***

7.58 ± 5.67***

SK-N-DZ

0 Gy

100 ± 10.12

100 ± 9.28

100 ± 17.87

2 Gy

51.97 ± 4.34

40.35 ± 10.15*

36.83 ± 17.71

5 Gy

40.06 ± 3.35

27.55 ± 3.86***

20.78 ± 12.76**

10 Gy

17.52 ± 3.23

8.25 ± 3.84**

5.20 ± 10.43*

  1. Table of cell viabilities (expressed as % of non-irradiated treatment control for a given concentration of nanoconjugates, after adjustment for baseline cytotoxicity) for SK-N-AS and SK-N-DZ cells treated with varying concentrations of DOPAC-nanocomposites combined with varying doses of ionizing radiation, from Fig. 5. Entries contain mean ± SD. *: < 0.05 significance level, **: < 0.01 significance level, *** < 0.001 significance level
Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us